Climent Miguel Ángel, León-Mateos Luis, González Del Alba Aránzazu, Pérez-Valderrama Begoña, Méndez-Vidal M José, Mellado Begoña, Arranz José Ángel, Sánchez-Hernández Alfredo, Cassinello Javier, Olmos David, Carles Joan
Instituto Valenciano de Oncología (IVO), Valencia, Spain.
Complexo Hospitalario Universitario de Pontevedra, Pontevedra, Spain.
Crit Rev Oncol Hematol. 2015 Nov;96(2):308-18. doi: 10.1016/j.critrevonc.2015.05.019. Epub 2015 Jun 8.
Prostate cancer is the most prevalent male urogenital malignancy. Approximately 30% of patients with prostate cancer will develop advanced disease. Androgen deprivation therapy achieves disease control in about 90% of these patients, but the majority of them will eventually develop progressive disease, a status called castration-resistant prostate carcinoma (CRPC). However, in recent years, several new therapy strategies, such as immunotherapy, hormonal manipulations, chemotherapy agents and some bone-targeted therapies, have demonstrated an improvement in terms of overall survival in controlled trials. In 2012, the Spanish Oncology Genitourinary Group (SOGUG) published its recommendations for the treatment of patients with CRPC. Due to the recent appearance of important new data and the complexity of decision-making in this field, SOGUG herein provides updated recommendations for the treatment of patients with metastatic prostate cancer.
前列腺癌是最常见的男性泌尿生殖系统恶性肿瘤。大约30%的前列腺癌患者会发展为晚期疾病。雄激素剥夺疗法能使约90%的此类患者病情得到控制，但其中大多数最终会发展为进展性疾病，即去势抵抗性前列腺癌（CRPC）。然而，近年来，一些新的治疗策略，如免疫疗法、激素操纵、化疗药物以及一些骨靶向疗法，在对照试验中已显示出总生存期有所改善。2012年，西班牙泌尿生殖系统肿瘤学组（SOGUG）发布了其关于CRPC患者治疗的建议。鉴于该领域近期出现的重要新数据以及决策的复杂性，SOGUG在此提供转移性前列腺癌患者治疗的更新建议。
